The update also rounds up the Awiqli pediatric approval, CagriSema subgroup data and the lost ad injunction against Lilly ahead of November 4 results.
Recap by typeshit. Full story at ad-hoc-news.de.
Beauty companies are reportedly exploring products aimed at facial volume loss in people who have lost weight on GLP-1 drugs.
A short Fox16 social clip points to GLP-1 users shifting how they drink when they go out, with the full story linked in the station's bio.
A Facebook share points to shifting drinking habits in pubs and bars as more people take GLP-1 medications, with the full story linked.
Food Dive reports the Atkins brand is shifting its pitch toward lapsed GLP-1 users, a growing group food companies are now chasing.
The bank sees room for another small guidance upgrade, but thinks investors will care more about where Novo goes next than about the quarter itself.
The analysis argues retatrutide is still unapproved, so the year-end price rides on Mounjaro and Zepbound, which made up about 65% of last quarter's revenue.
Loading…